The German biotech inks its fifth metabolic disease collaboration as it teams up with US major Eli Lilly to develop kidney disease and diabetes assets.

Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.

From a STING agonist to a SOS1 inhibitor, Lupin listed oncology candidates from the preclinical stage to those in IND-enabling studies during the recently concluded J.P. Morgan conference. Meanwhile, the newly spun-off oncology subsidiary awaits partners.

Chaos wrought by the ongoing coronavirus pandemic. A heavy workload and continuing resource constraints at the European Medicines Agency. Nonetheless, a record number of novel drugs and vaccines were cleared for marketing in the EU last year.